Neovasc is Creating
for the Treatment of
Advanced Heart Disease
PR Martine Gilard de la Société Française de Cardiologie annonce le lancement officiel du registre « France Réducteur ».
A LEADER IN CARDIOVASCULAR INNOVATION
The company is committed to clinical rigor and collaborates with researchers and clinicians in Canada, the United States, Europe, and the Middle East. Our products, the Reducer™ and Tiara™ systems, represent the forefront of innovation in treating advanced heart disease.
Reducer is CE-marked for use in the EU and is FDA approved for investigational use in the US. Tiara is not commercially available and is currently being evaluated in two ongoing clinical trials.
Headquartered in Vancouver, BC and Minneapolis, MN, Neovasc is publicly traded on both the NASDAQ and the Toronto Stock Exchange (NVCN).
13700 Mayfield Place #2135
Richmond BC V6V 2E4
900 Long Lake Road
New Brighton, MN 55112